Short Interest in Ipsen S.A. (OTCMKTS:IPSEY) Expands By 107.1%

Ipsen S.A. (OTCMKTS:IPSEY) was the target of a large growth in short interest during the month of December. As of December 31st, there was short interest totalling 2,900 shares, a growth of 107.1% from the December 15th total of 1,400 shares. Based on an average trading volume of 2,300 shares, the days-to-cover ratio is presently 1.3 days.

Ipsen Stock Up 1.5 %

IPSEY traded up $0.47 during trading hours on Thursday, reaching $31.68. The company’s stock had a trading volume of 612 shares, compared to its average volume of 790. The company’s 50-day moving average is $29.03 and its 200-day moving average is $29.67. Ipsen has a 52 week low of $27.00 and a 52 week high of $34.06.

Ipsen Company Profile

Ipsen SA operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial.